Strategies to Prevent Surgical Site Infections in Acute Care Hospitals: 2014 Update

Deverick J. Anderson, MD, MPH; Kelly Podgorny, DNP, MS, RN; Sandra I. Berrios-Torres, MD; Dale W. Bratzler, DO, MPH; E. Patchen Dellinger, MD; Linda Greene, RN, MPS, CIC; Ann-Christine Nyquist, MD, MSPH; Lisa Saiman, MD, MPH; Deborah S. Yokoe, MD, MPH; Lisa L. Maragakis, MD, MPH; Keith S. Kaye, MD, MPH

P R O V I D E D BY:
SHEA/IDSA PRACTICE RECOMMENDATION

P U R P O S E

Previously published guidelines are available that provide comprehensive recommendations for detecting and preventing healthcare-associated infections (HAIs). The intent of this document is to highlight practical recommendations in a concise format designed to assist acute care hospitals in implementing and prioritizing their surgical site infection (SSI) prevention efforts. This document updates “Strategies to Prevent Surgical Site Infections in Acute Care Hospitals,” published in 2008. This expert guidance document is sponsored by the Society for Healthcare Epidemiology of America (SHEA) and is the product of a collaborative effort led by SHEA, the Infectious Diseases Society of America (IDSA), the American Hospital Association (AHA), the Association for Professionals in Infection Control and Epidemiology (APIC), and The Joint Commission, with major contributions from representatives of a number of organizations and societies with content expertise. The list of endorsing and supporting organizations is presented in the introduction to the 2014 updates.

S E C T I O N 1: R A T I O N A L E A N D S T A T E M E N T S O F C O N C E R N

I. SSIs are common complications in acute care facilities
   A. SSIs occur in 2%–5% of patients undergoing inpatient surgery.
   B. Approximately 160,000–300,000 SSIs occur each year in the United States.
   C. SSIs are now the most common and most costly HAI.

II. Outcomes associated with SSI
   A. Up to 60% of SSIs have been estimated to be preventable by using evidence-based guidelines.
   B. SSIs account for 20% of all HAIs in hospitalized patients.
   C. Each SSI is associated with approximately 7–11 additional postoperative hospital-days.
   D. Patients with an SSI have a 2–11-times higher risk of death compared with operative patients without an SSI.
   E. Seventy-seven percent of deaths in patients with SSI are directly attributable to SSI.
   F. Attributable costs of SSI vary depending on the type of operative procedure and the type of infecting pathogen.

II. Surveillance definitions
   A. The Centers for Disease Control and Prevention’s (CDC’s) National Healthcare Safety Network (NHSN) definitions for SSI are widely used for public reporting, interfacility comparison, and pay-for-performance comparisons.
   B. SSIs are classified (Figure 1) as follows:
      1. Superficial incisional (involving only skin or subcutaneous tissue of the incision).
2. Deep incisional (involving fascia and/or muscular layers).
   a. Deep incision primary (DIP)—SSI identified in a primary incision in a patient who has had an operation with 1 or more incisions.
   b. Deep incision secondary (DIS)—SSI identified in a secondary incision in a patient who has had an operation with more than 1 incision.
3. Organ/space (involving any part of the body opened or manipulated during the procedure, excluding skin incision, fascia, or muscle layers).

II. Methods for surveillance of SSI
A. The direct method with daily observation of the surgical site by the physician, physician extender, registered nurse, or infection prevention and control (IPC) professional starting 24–48 hours postoperatively is the most accurate method of surveillance.13,27-29
   1. While the direct method is used as the gold standard for studies, it is rarely used in practice because of its resource utilization requirements and impracticality.
B. The indirect method of SSI surveillance consists of a combination of the following:
   1. Review of microbiology reports and patient medical records.
   2. Surgeon and/or patient surveys.
   3. Screening for readmission and/or return to the operating room.
   4. Other information, such as coded diagnoses, coded procedures, operative reports, or antimicrobials ordered.
C. The indirect method of SSI surveillance is less time-consuming and can be readily performed by IPC personnel during surveillance rounds.
D. The indirect method of SSI surveillance is both reliable (sensitivity, 84%–89%) and specific (specificity, 99.8%) compared with the gold standard of direct surveillance.30,31 Components of the indirect methods that were associated with highest sensitivities included review of nursing notes, International Classification of Diseases, Ninth Revision codes, and antimicrobials used.
E. Indirect methods for SSI surveillance are not reliable for surveillance of superficial incisional infections, particularly those occurring postdischarge.32
F. Automated data systems can be used to broaden SSI surveillance.
   1. SSI surveillance can be expanded by utilizing hospital databases that include administrative claims data (including diagnosis and procedure codes), antimicrobial-days, readmission to the hospital, and return to the operating room and/or by implementing a system that imports automated microbiologic culture data, surgical procedure data, and general demographic information into a single surveillance database.33-35
   2. These methods improve the sensitivity of indirect surveillance for detection of SSI and reduce the effort of the infection preventionist.35
   3. Medicare claims data can be used to enhance traditional surveillance methods for SSI and to identify hospitals with unusually high or low rates of SSI.36,37
   4. Use of administrative data can increase the efficiency of SSI reporting and validation.38

III. Postdischarge surveillance
A. Over the past 3 decades, advances in medical technology and changes in payment arrangements have increasingly shifted performance of surgical procedures from
the acute care setting to the ambulatory (free-standing or hospital-affiliated) outpatient care setting.

B. Concurrently, postoperative hospital length of stay has steadily declined. These trends highlight the increasing importance of postdischarge surveillance, without which SSI rates will be underestimated and opportunities for improvements in healthcare delivery, patient safety, and SSI prevention will be missed.

C. The proportion of SSIs detected through postdischarge surveillance can vary by surveillance method, operative setting, type of SSI, and surgical procedure.

1. No standardized or reliable method for postdischarge surveillance has been established. Postdischarge surveillance based on surgeon and patient questionnaire results have been shown to have poor sensitivity and specificity.

2. The ambulatory care setting represents a challenge because patients do not return to it for routine postoperative care or for management of complications. Research is needed to better understand how definitions and postdischarge surveillance protocols developed for the acute care setting can be translated to the ambulatory care setting.

3. Superficial incisional SSIs are most commonly detected and managed in the outpatient setting. In contrast, deep incisional and organ/space infections typically require readmission to the hospital for management.

4. In the Netherlands, the proportion of deep SSIs identified after discharge from the hospital ranged from 6% for colon resections to 88% for knee arthroplasties. The differences between these procedures could be explained by potential differences in both wound contamination class and the duration of postdischarge surveillance (30 days versus 1 year for an implant-related procedure). A pilot study in general surgery reported that 10.5% of SSIs following colon procedures were identified after discharge from the hospital.

5. By improving completeness of reporting, the overall institutional SSI rate typically increases after postdischarge surveillance methods are implemented regardless of which method is used.

a. To improve interfacility comparisons and minimize potential bias introduced by differences in postdischarge surveillance methods, national public reporting focuses on nonsuperficial incisional SSIs detected during hospitalization for the index procedure or after discharge and requiring readmission for management.

SECTION 3: BACKGROUND—STRATEGIES TO PREVENT SSI

1. Summary of existing guidelines, recommendations, and requirements

A. CDC and Healthcare Infection Control Practices Advisory Committee (HICPAC) guidelines

1. The most recently published guideline for prevention of SSIs was released in 1999 by Mangram et al. The CDC and HICPAC are currently working on an updated version of the guideline with a projected publication date in mid-2014.

B. National Institute for Health and Clinical Excellence (NICE)—United Kingdom


C. Surgical Infection Prevention (SIP) Project

1. The Centers for Medicare & Medicaid Services (CMS) created the SIP project in 2002.

a. After review of published guidelines, an expert panel identified 3 performance measures for quality improvement related to antimicrobial prophylaxis:

i. Delivery of intravenous antimicrobial prophylaxis within 1 hour before incision (2 hours are allowed for the administration of vancomycin and fluoroquinolones).

ii. Use of an antimicrobial prophylactic agent consistent with published guidelines.

iii. Discontinuation of the prophylactic antimicrobial agent within 24 hours after surgery (discontinuation within 48 hours is allowable for cardiothoracic procedures in adult patients).

b. The SIP project focused on 7 procedures: abdominal hysterectomy, vaginal hysterectomy, hip arthroplasty, knee arthroplasty, cardiac surgery, vascular surgery, and colorectal surgery.

c. Many hospitals that implemented and improved compliance with SIP performance measures decreased their rates of SSI.

D. Surgical Care Improvement Project (SCIP)

1. The SCIP, a multiagency collaboration created in 2003, is an extension of SIP.

2. In addition to the 3 performance measures of SIP, the SCIP also focuses on 3 additional evidence-supported process measures to prevent SSIs and expanded the types of operations eligible for the performance measures.

a. Proper hair removal: no hair removal, although hair removal with clippers or the depilatory method is considered appropriate. Use of razors is considered inappropriate with exception of use on the scrotal area or on the scalp after a traumatic head injury. Because of near-universal compliance with this performance measure, CMS retired the measure in 2012.

b. Controlling blood glucose during the immediate postoperative period for cardiac surgery patients: controlled 6 AM blood glucose (200 mg/dL or lower) on postoperative days 1 and 2, with the procedure day being postoperative day 0. In 2014, this measure will be revised to assess glucose control (180 mg/dL or lower) in cardiac surgery pa-
II. Infrastructure requirements

A. Trained personnel

1. Infection preventionists must (1) be specifically trained in methods of SSI surveillance, (2) have knowledge of and the ability to prospectively apply the CDC/NHSN definitions for SSI, (3) possess basic computer and mathematical skills, and (4) be adept at providing feedback and education to healthcare personnel when appropriate.17

B. Education

1. Regularly provide education to surgeons and perioperative personnel through continuing education activities directed at minimizing perioperative SSI risk through implementation of recommended process measures.

C. Computer-assisted decision support and automated reminders

1. Several institutions have successfully employed computer-assisted decision support methodology to improve the rate of appropriate administration of antimicrobial prophylaxis (including redosing during prolonged cases).70-73

2. Computer-assisted decision support, however, is potentially expensive, can be time-consuming to implement, and in a single study was reported to initially increase the rate of adverse drug reactions.74

3. Institutions must appropriately validate computer-assisted decision support systems after implementation.

D. Utilization of automated data

1. Install information technology infrastructure to facilitate data transfer, receipt, and organization to aid with tracking of process and outcome measures.

SECTION 4: RECOMMENDED STRATEGIES FOR SSI PREVENTION

Recommendations are categorized as either (1) basic practices that should be adopted by all acute care hospitals or (2) special approaches that can be considered for use in locations and/or populations within hospitals when HAIs are not controlled by use of basic practices. Basic practices include recommendations where the potential to impact HAI risk clearly outweighs the potential for undesirable effects. Special approaches include recommendations where the intervention is likely to reduce HAI risk but where there is concern about the risks for undesirable outcomes resulting from the intervention, where the quality of evidence is low, or where evidence supports the impact of the intervention in select settings (eg, during outbreaks) or for select patient populations. Hospitals can prioritize their efforts by initially focusing on implementation of the prevention approaches listed as basic practices. If HAI surveillance or other risk assessments suggest that there are ongoing opportunities for improvement, hospitals should then consider adopting some or all of the prevention approaches listed as special approaches. These can be implemented in specific locations or patient populations or can be implemented hospital-wide, depending on outcome data, risk assessment, and/or local requirements. Each infec-
### Table 1. Grading of the Quality of Evidence

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. High</td>
<td>Highly confident that the true effect lies close to that of the estimated size and direction of the effect. Evidence is rated as high quality when there is a wide range of studies with no major limitations, there is little variation between studies, and the summary estimate has a narrow confidence interval.</td>
</tr>
<tr>
<td>II. Moderate</td>
<td>The true effect is likely to be close to the estimated size and direction of the effect, but there is a possibility that it is substantially different. Evidence is rated as moderate quality when there are only a few studies and some have limitations but not major flaws, there is some variation between studies, or the confidence interval of the summary estimate is wide.</td>
</tr>
<tr>
<td>III. Low</td>
<td>The true effect may be substantially different from the estimated size and direction of the effect. Evidence is rated as low quality when supporting studies have major flaws, there is important variation between studies, the confidence interval of the summary estimate is very wide, or there are no rigorous studies, only expert consensus.</td>
</tr>
</tbody>
</table>

**Note.** Based on Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) and the Canadian Task Force on Preventive Health Care.
Optimize tissue oxygenation by administering supplemental oxygen during and immediately following surgical procedures involving mechanical ventilation (quality of evidence: I).

a. Supplemental oxygen is most effective when combined with additional strategies to improve tissue oxygenation, including maintenance of normothermia and appropriate volume replacement. The available evidence is in patients undergoing surgery with general anesthesia using mechanical ventilation.106-108

i. Seven randomized clinical trials have been published comparing 80% with 30%–35% \( \text{FiO}_2 \) (4 with nitrogen106-109 and 3 with nitrous oxide110-112) in patients undergoing general anesthesia with intraoperative mechanical ventilation and postoperative oxygen delivered for 2–6 hours via a non-rebreathing mask.

ii. Three trials in patients undergoing elective colorectal resection106,107,111 and 1 each in open appendectomy108 and total gastrectomy with esophagojejunai anastomosis112 reported an approximate 40% decrease in the rate of SSI. Three of the studies reported protocols that included maintenance of perioperative normothermia and liberal fluid replacement.106-108

iii. Two trials in mixed surgical populations undergoing emergency or elective laparotomy for gastrointestinal, gynecologic, or urologic procedures reported different results.109,110

(a) The large multicenter trial that restricted perioperative fluid replacement reported no difference.110 A follow-up study performed in this population noted that patients undergoing cancer surgery who received 80% \( \text{FiO}_2 \) had higher rates of mortality than patients undergoing cancer surgery who received 30% \( \text{FiO}_2 \).113

(b) The smaller trial without standardized protocols for perioperative normothermia or volume replacement reported an increase in SSIs.110 In this study, the 80% \( \text{FiO}_2 \) group had a significantly higher proportion of patients with high body mass index (more than 30), higher blood loss, more crystalloid infused, and longer operations. This group also had 5 patients who remained intubated postoperatively (vs 1 in the 35% group). Postoperative intubation was predictive of SSI.

b. A meta-analysis of 5 of the above-referenced studies concluded that perioperative supplemental oxygen led to a relative risk (RR) reduction of 25% for SSI.114

6. Use alcohol-containing preoperative skin preparatory agents if no contraindication exists (quality of evidence: I).

a. Alcohol is highly bactericidal and effective for preoperative skin antisepsis but does not have persistent activity when used alone. Rapid, persistent, and cumulative antisepsis can be achieved by combining alcohol with chlorhexidine gluconate or an iodophor.115

i. Alcohol is contraindicated for certain procedures, including procedures in which the preparatory agent may pool or not dry (eg, involving hair) due to fire risk. Alcohol may also be contraindicated for procedures involving mucosa, cornea, or ear.

b. The most effective disinfectant to combine with alcohol is unclear.

i. A recent trial of 849 patients undergoing clean-contaminated surgery randomized patients to preoperative skin antisepsis with chlorhexidine-alcohol or povidone-iodine.116 The overall rate of SSI was significantly lower in the chlorhexidine-alcohol group than in the povidone-iodine group (9.5% vs 16% \( P = .004 \); RR, 0.59 [95% confidence interval (CI), 0.41–0.85]).

ii. In contrast, a single-center study compared povidone-iodine followed by isopropyl alcohol versus chlorhexidine-alcohol versus iodine-alcohol using a sequential implementation design.117 General surgical patients who received skin antisepsis with iodine-alcohol had the lowest rates of SSI (3.9 per 100 procedures), compared with 6.4 per 100 procedures for patients who received povidone-iodine followed by alcohol and 7.1 per 100 procedures for patients who received chlorhexidine-alcohol.
a. Identify high-risk, high-volume operative procedures to be targeted for SSI surveillance on the basis of a risk assessment of patient populations, operative procedures performed, and available SSI surveillance data.

b. Identify, collect, store, and analyze data needed for the surveillance program.  
   i. Develop a database for storing, managing, and accessing data collected on SSI.
   ii. Implement a system for collecting data needed to identify SSI. Data are required from surgical and microbiological databases. Obtain the following data from surgical databases: patient name, medical record number, date, type of procedure, surgeons, anesthesiologists, incision time, wound class, ASA score, closure time, and presence of an SSI. Ideally, these data are supplemented with process data, including prophylactic agent and dose and time(s) of administration of prophylactic agent. For patients diagnosed with an SSI, necessary microbiological data include type of SSI, infecting organism and antimicrobial susceptibilities, and date of infection. More detailed surgical and patient information may be useful for some procedures, including use of general anesthesia, emergency or trauma-related surgery, body mass index, and diagnosis of diabetes.

iii. Prepare periodic SSI reports (time frame will depend on hospital needs and volume of targeted procedures).

iv. Collect denominator data on all patients undergoing targeted procedures in order to calculate SSI rates for each type of procedure.  

v. Identify trends (eg, in SSI rates and pathogens causing SSI).

c. Use updated CDC NHSN definitions for SSI.  
d. Perform indirect surveillance for targeted procedures.  

e. Perform postoperative surveillance for 30 days; extend the postoperative surveillance period to 90 days for certain procedure categories.

i. Procedures that require 90-day surveillance are determined by specific procedure codes.

f. Surveillance should be performed on patients readmitted to the hospital.

i. If an SSI is diagnosed at your institution but the surgical procedure was performed elsewhere, notify the hospital where the original procedure was performed.

g. Develop a system for routine review and interpretation of SSI rates to detect significant increases or outbreaks and to identify areas where additional resources might be needed to improve SSI rates. If increased rates are identified, determine the number of potentially preventable infections that occurred, defined as the number of SSI that occurred during a procedure in which less than 100% of recommended practices and processes were completed.

10. Increase the efficiency of surveillance through utilization of automated data (quality of evidence: II).  
a. Implement a method to electronically transfer microbiology and operative data, including process measures when available, to IPC personnel to facilitate denominator data acquisition and calculation of SSI rates for various procedures.

b. If information technology and infrastructure resources are available, develop automated methods for detection of SSI utilizing automated data for readmissions, diagnosis and procedure codes, microbiology results, and antimicrobial dispensing.

c. Implementation of automated surveillance may improve the sensitivity of surveillance.

11. Provide ongoing feedback of SSI rates to surgical and perioperative personnel and leadership (quality of evidence: II).  
a. Routinely audit and provide confidential feedback on SSI rates and adherence to process measures to in-
dividual surgeons, the surgical division and/or department chiefs, and hospital leadership.17,130
i. For each type of procedure performed, provide risk-adjusted rates of SSI.

12. Measure and provide feedback to providers regarding rates of compliance with process measures (quality of evidence: III).14
a. Routinely provide feedback to surgical staff, perioperative personnel, and leadership regarding compliance with targeted process measures.

   a. Include risk factors, outcomes associated with SSI, local epidemiology (eg, SSI rates by procedure, rate of methicillin-resistant Staphylococcus aureus [MRSA] infection in a facility), and basic prevention measures.
   b. Examples of printed materials for patients are available from the following websites:
      iv. SSI: resources for patients and healthcare providers (available from the CDC at http://www.cdc.gov/hai/ssi/ssi.html).

15. Implement policies and practices aimed at reducing the risk of SSI that align with evidence-based standards (eg, CDC, Association for periOperative Registered Nurses, and professional organization guidelines; quality of evidence: II).15,18,132
a. The pathogenesis and likelihood of developing an SSI involves a complex relationship among the following:
   i. Microbial characteristics (eg, degree of contamination, virulence of pathogen);
   ii. Patient characteristics (eg, immune status, comorbid conditions); and
   iii. Surgical characteristics (eg, type of procedure, introduction of foreign material, amount of damage to tissues).133
b. Risk factors for SSI can be separated into intrinsic patient-related characteristics and extrinsic procedure-related characteristics. Implement policies and practices to reducing modifiable risk factors (Table 2), including the following:
   i. Optimal preparation and disinfection of the operative site and the hands of the surgical team members.
   ii. Adherence to hand hygiene, including nonsurgeon members of the operating team.134
   iii. Reduce unnecessary traffic in operating rooms.135,136
   iv. Appropriate care and maintenance of operating rooms, including appropriate air handling and optimal cleaning and disinfection of equipment and the environment.17

II. Special approaches for preventing SSI

Standard infection control methods of outbreak investigation are recommended for use in locations and/or populations within the hospital with unacceptably high SSI rates despite implementation of the basic SSI prevention strategies listed above.

1. Screen for S. aureus and decolonize surgical patients with an antistaphylococcal agent in the preoperative setting for high-risk procedures, including some orthopedic and cardiothoracic procedures (quality of evidence: II).
   a. Screening for S. aureus refers to the practice of attempting to identify patients colonized with methicillin-susceptible S. aureus (MSSA) and/or MRSA. Decolonization refers to the practice of treating patients with known S. aureus colonization with antimicrobial and/or antiseptic agents to eliminate S. aureus colonization.
   i. There is no standardized approach to either screening or decolonizing. Most clinicians attempt to decolonize surgical patients with a combination of chlorhexidine gluconate applied to the skin and nasal mupirocin.
   b. A Cochrane review concluded that mupirocin alone may be effective, particularly in certain groups, including orthopedic and cardiothoracic patients.137
   c. Clinical practice guidelines from the American Society of Health-System Pharmacists recommend giving mupirocin intranasally to all patients with documented S. aureus colonization for orthopedic procedures, including total joint replacement and hip fracture repair, and cardiac procedures.76
   d. Some trials demonstrate that preoperative screening for S. aureus, coupled with intranasal mupirocin and chlorhexidine bathing is effective in reducing SSI for some patients.
   i. For example, a randomized, double-blind, placebo-controlled, multicenter trial that evaluated rapid identification of S. aureus nasal carriers followed
### Table 2. Selected Risk Factors for and Recommendations to Prevent Surgical Site Infections (SSIs)

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Recommendation</th>
<th>Quality of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intrinsic, patient related (preoperative)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unmodifiable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>No formal recommendation. Relationship to increased risk of SSI may be secondary to comorbidities or immunosenescence. 216-218</td>
<td>NA</td>
</tr>
<tr>
<td>History of radiation</td>
<td>No formal recommendation. Prior irradiation at the surgical site increases the risk of SSI, likely due to tissue damage and wound ischemia. 219</td>
<td>NA</td>
</tr>
<tr>
<td>History of SSTIs</td>
<td>No formal recommendation. History of a prior skin infection may be a marker for inherent differences in host immune function. 220</td>
<td>NA</td>
</tr>
<tr>
<td>Modifiable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose control</td>
<td>Control serum blood glucose levels for all surgical patients, including patients without diabetes. 17 For patients with diabetes mellitus, reduce glycosylated hemoglobin A1c levels to less than 7% before surgery, if possible. 94</td>
<td>I</td>
</tr>
<tr>
<td>Obesity</td>
<td>Increase dosing of prophylactic antimicrobial agent for morbidly obese patients. 76,221</td>
<td>I</td>
</tr>
<tr>
<td>Smoking cessation</td>
<td>Encourage smoking cessation within 30 days of procedure. 17,222-226</td>
<td>I</td>
</tr>
<tr>
<td>Immunosuppressive medications</td>
<td>Avoid immune-suppressive medications in perioperative period, if possible.</td>
<td>III</td>
</tr>
<tr>
<td>Hypoalbuminemia</td>
<td>No formal recommendation. Although a noted risk factor, 227 do not delay surgery for use of TPN.</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Extrinsic, procedure related (perioperative)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preparation of patient</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hair removal</td>
<td>Do not remove unless hair will interfere with the operation. 17 If hair removal is necessary, remove outside the OR by clipping. Do not use razors.</td>
<td>II</td>
</tr>
<tr>
<td>Preoperative infections</td>
<td>Identify and treat infections (eg, urinary tract infection) remote to the surgical site prior to elective surgery. 17 Do not routinely treat colonization or contamination.</td>
<td>II</td>
</tr>
<tr>
<td>Operative characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical scrub (surgical team members’ hands and forearms)</td>
<td>Use appropriate antiseptic agent to perform preoperative surgical scrub. 17,228 For most products, scrub the hands and forearms for 2–5 minutes.</td>
<td>II</td>
</tr>
<tr>
<td>Skin preparation</td>
<td>Wash and clean skin around incision site. Use a dual agent skin preparation containing alcohol, unless contraindications exist. 27</td>
<td>I</td>
</tr>
<tr>
<td>Antimicrobial prophylaxis</td>
<td>Administer only when indicated. 17</td>
<td>I</td>
</tr>
<tr>
<td>Timing</td>
<td>Administer within 1 hour of incision to maximize tissue concentration. 76a</td>
<td>I</td>
</tr>
<tr>
<td>Blood transfusion</td>
<td>Blood transfusions increase the risk of SSI by decreasing macrophage function. Reduce blood loss and need for blood transfusion to the greatest extent possible. 229-231</td>
<td>II</td>
</tr>
<tr>
<td>Choice of prophylactic agent</td>
<td>Select appropriate agents on the basis of surgical procedure, most common pathogens causing SSIs for a specific procedure, and published recommendations. 29</td>
<td>I</td>
</tr>
<tr>
<td>Duration of prophylaxis</td>
<td>Stop agent within 24 hours after the procedure for all procedures. 26</td>
<td>II</td>
</tr>
<tr>
<td>Surgeon skill/technique</td>
<td>Handle tissue carefully and eradicate dead space. 17</td>
<td>III</td>
</tr>
<tr>
<td>Appropriate gloving</td>
<td>All members of the operative team should double glove and change gloves when perforation is noted. 208</td>
<td>III</td>
</tr>
<tr>
<td>Asepsis</td>
<td>Adhere to standard principles of OR asepsis. 17</td>
<td>III</td>
</tr>
<tr>
<td>Operative time</td>
<td>No formal recommendation in most recent guidelines. Minimize as much as possible without sacrificing surgical technique and aseptic practice.</td>
<td>I</td>
</tr>
<tr>
<td><strong>OR characteristics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ventilation</td>
<td>Follow American Institute of Architects’ recommendations for proper air handling in the OR. 17,231</td>
<td>III</td>
</tr>
<tr>
<td>Traffic</td>
<td>Minimize OR traffic. 17,135,136</td>
<td>III</td>
</tr>
<tr>
<td>Environmental surfaces</td>
<td>Use an EPA-approved hospital disinfectant to clean visibly soiled or contaminated surfaces and equipment. 37</td>
<td>III</td>
</tr>
<tr>
<td>Sterilization of surgical equipment</td>
<td>Sterilize all surgical equipment according to published guidelines. 225 Mini-mize the use of immediate-use steam sterilization. 225</td>
<td>II</td>
</tr>
</tbody>
</table>

**Note.** EPA, Environmental Protection Agency; NA, not applicable; OR, operating room; SSTI, skin and soft-tissue infection; TPN, total parenteral nutrition.

* Vancomycin and fluoroquinolones can be given 2 hours prior to incision.
by decolonization was associated with a greater than 2-fold reduction in the risk for postoperative infection due to *S. aureus* and an almost 5-fold reduction in risk for deep incisional SSI due to *S. aureus*.141

(a) This study was performed in a setting with high baseline rates of SSI and in the absence of MRSA.

e. In contrast, other trials have failed to demonstrate a benefit.

i. A prospective, interventional cohort study with a crossover design involving 21,000 patients concluded that universal, rapid screening for MRSA at admission coupled with decolonization of carriers did not reduce the rate of SSI due to MRSA.142

ii. A double-blind randomized controlled trial involving more than 4,000 patients showed that intranasal application of mupirocin, which was not coupled with chlorhexidine bathing, did not significantly reduce the *S. aureus* SSI rate.143

(a) In a secondary analysis of these data, the use of intranasal mupirocin was associated with an overall decreased rate of nosocomial *S. aureus* infections among the *S. aureus* carriers.

f. A recently published meta-analysis of 17 studies concluded that decolonization strategies prevent gram-positive SSIs, *S. aureus* SSIs, and MRSA SSIs, although there was significant heterogeneity among the trials.144

g. Factors that impact the decision to implement screening for *S. aureus* and decolonization include adherence to basic SSI prevention strategies, baseline rate of SSI due to *S. aureus*, individual patient risk factors for acquiring SSI due to *S. aureus*, availability of resources to implement the protocol, and ability to follow-up on protocol parameters (eg, laboratory results) and adherence.

h. Routine preoperative decolonization with mupirocin without screening is not currently recommended.

i. Mupirocin resistance has been documented.145


a. Wound lavage is a common practice, although the solution used for lavage differs among surgeons.146

b. Several groups have evaluated whether dilute povidone-iodine lavage of the surgical wound can decrease the risk of SSI. A meta-analysis published in 2010 evaluated 24 randomized controlled trials and concluded that lavage with dilute povidone-iodine decreased the risk of SSI compared with nonantiseptic lavage (RR, 0.64 [95% CI, 0.51–0.82]).147


a. Convene a multidisciplinary team (eg, surgical leadership, hospital administration, quality management services, and infection control) to identify gaps, improve performance, measure compliance, assess impact of interventions, and provide feedback.148

b. Determine baseline SSI rates by surgical specialty, procedure, and/or surgeon to better target your evaluation and interventions.

4. Observe and review operating room personnel and the environment of care in the operating room (quality of evidence: III).

a. Perform direct observation audits of operating room personnel to assess operating room processes and practices to identify infection control lapses, including but not limited to adherence to process measures ( antimicrobial prophylaxis choice, timing and duration protocols, hair removal, etc), surgical hand antisepsis, patient skin preparation, operative technique, surgical attire (wearing and/or laundering outside the operating room), and level of operating room traffic.149-150 Perform remediation when breaches of standards are identified.

i. Operating room personnel should include surgeons, surgical technologists, anesthesiologists, circulating nurses, residents, medical students, trainees, and device manufacturer representatives.149

b. Perform direct-observation audits of environmental cleaning practices in the operating room, instrument processing (sterilization), and storage facilities.

i. Review instrument processing and flash sterilization logs.

ii. Review maintenance records for operating room heating, ventilation, and air conditioning system, including results of temperature and relative humidity testing, and test for maintenance of positive air pressure in the operating room(s).

c. Provide feedback and review infection control measures with operating room and environmental personnel.

5. Observe and review practices in the postanesthesia care unit, surgical intensive care unit, and/or surgical ward (quality of evidence: II).

a. Perform direct observation audits of hand hygiene practices among all personnel with direct patient contact.151

b. Evaluate wound care practices.154

c. Perform direct observation audits of environmental cleaning practices.

d. Provide feedback and review infection control measures with staff in these postoperative care settings.

III. Approaches that should not be considered a routine part of SSI prevention

1. Do not routinely use vancomycin for antimicrobial prophylaxis (quality of evidence: II).152,153

a. Vancomycin should not routinely be used for antimicrobial prophylaxis, but it can be an appropriate agent for specific scenarios. Reserve vancomycin for specific clinical circumstances, such as a proven outbreak of SSI due to MRSA; high endemic rates of SSI due to MRSA; targeted high-risk patients who are at...
increased risk for SSI due to MRSA (including cardiothoracic surgical patients and elderly patients with diabetes); and high-risk surgical procedures in which an implant is placed.156

i. No definitions for high endemic rates of SSI due to MRSA have been established.157

ii. Studies of the efficacy of vancomycin prophylaxis were published prior to the emergence of community-acquired MRSA.

b. Two meta-analyses of studies comparing glycopeptides to β-lactam antimicrobial prophylaxis concluded that there was no difference in rates of SSI between the 2 antimicrobial prophylaxis regimens.144,158

c. A meta-analysis of 6 studies concluded that prophylaxis with a glycopeptide and a second agent was protective against SSI due to gram-positive organisms compared with prophylaxis with a β-lactam alone.144 Of note, the 2 randomized controlled trials included in the meta-analysis combined a glycopeptide with non-β-lactam antibiotic(s). Thus, no study has prospectively analyzed the effect of providing both glycopeptides and β-lactam antimicrobials for preoperative antimicrobial prophylaxis. As vancomycin does not have activity against gram-negative pathogens and appears to have less activity against MSSA than β-lactam agents, many experts recommend adding vancomycin to standard antimicrobial prophylaxis for the specific clinical circumstances described above.78,157-159

2. Do not routinely delay surgery to provide parenteral nutrition (quality of evidence: I).

a. Preoperative administration of total parenteral nutrition has not been shown to reduce the risk of SSI in prospective randomized controlled trials and may increase the risk of SSI.160,161

b. Individual trials comparing enteral and parenteral perioperative nutrition and “immunomodulating” diets containing arginine and/or glutamine with “standard” control diets tend to have very small numbers and fail to show significant differences. Two recent meta-analyses, however, demonstrate reduction in postoperative infectious complication in patients receiving enteral diets containing glutamine and/or arginine administered either before or after the surgical procedure.162,163

3. Do not routinely use antiseptic-impregnated sutures as a strategy to prevent SSIs (quality of evidence: II).

a. Human volunteer studies involving foreign body have demonstrated that the presence of surgical sutures decreases the inoculum required to cause an SSI from 10^6 to 10^2 organisms.164

b. Some trials have shown that surgical wound closure with triclosan-coated polygactin 910 antimicrobial sutures may decrease the risk of SSI compared with standard sutures. For example, a recent randomized controlled trial of 410 colorectal surgeries concluded that the rate of SSI decreased more than 50% (9.3% in the control group vs 4.3% among cases; P = .05).165

c. In contrast, a recent systematic review and meta-analysis evaluated 7 randomized clinical trials and concluded that neither rates of SSI (odds ratio [OR], 0.77 [95% CI, 0.4–1.51]; P = .45) nor rates of wound dehiscence (OR, 1.07 [95% CI, 0.21–5.43]; P = .93) were statistically different compared with controls.166 In addition, one small study raised concern about higher rates of wound dehiscence while using these sutures.167

d. The impact of routine use of antiseptic-impregnated sutures on development of resistance to antiseptics is unknown.

4. Do not routinely use antiseptic drapes as a strategy to prevent SSIs (quality of evidence: I).

a. An incise drape is an adhesive film that covers the surgical incision site to minimize bacterial wound contamination due to endogenous flora. These drapes can be impregnated with antiseptic chemicals, such as iodophors.

b. A 2007 Cochrane review of 5 trials concluded that nonantiseptic incise drapes were associated with a higher risk of SSI compared with no incise drape (RR, 1.23 [95% CI, 1.02–1.48]),166 although this association may have been caused by one specific study.169 Two trials (abdominal and cardiac surgical patients) compared iodophor-impregnated drapes to no drapes.170,171 While wound contamination was decreased in one trial,170 neither trial demonstrated that iodophor-impregnated drapes decreased the rate of SSI. A nonrandomized retrospective study similarly concluded that impregnated drapes do not prevent SSIs after hernia repair.172

IV. Unresolved Issues

1. Preoperative bathing with chlorhexidine-containing products.

a. Preoperative bathing with agents such as chlorhexidine has been shown to reduce bacterial colonization of the skin.173 Several studies have examined the utility of preoperative showers, but none has definitively proven that they decrease SSI risk. A Cochrane review evaluated the evidence for preoperative bathing or showering with antiseptics for SSI prevention.174 Six randomized controlled trials evaluating the use of 4% chlorhexidine gluconate were included in the analysis, with no clear evidence of benefit noted. It should be noted that several of these studies had methodological limitations and were conducted several years ago. Thus, the role of preoperative bathing in SSI prevention is still uncertain.

i. To gain the maximum antiseptic effect of chlorhexidine, adequate levels of CHG must be achieved and maintained on the skin. Typically, adequate levels are achieved by allowing CHG to dry com-
pletely. New strategies for preoperative bathing with chlorhexidine, such as preimpregnated cloths, have shown promise,\textsuperscript{175,176} but data are currently insufficient to support this approach.

2. Preoperative intranasal and pharyngeal chlorhexidine treatment for patients undergoing cardiothoracic procedures.
   a. Although data from a randomized controlled trial exist to support the use of chlorhexidine nasal cream combined with 0.12% chlorhexidine gluconate mouthwash,\textsuperscript{177} chlorhexidine nasal cream is neither approved by the Food and Drug Administration (FDA) nor commercially available in the United States.

3. Use of gentamicin-collagen sponges.
   a. Gentamicin-collagen sponges have been evaluated as a way to decrease SSI among colorectal and cardiac surgical patients.
      i. Colorectal surgical patients. Several single-center randomized trials have demonstrated that gentamicin-collagen sponges decrease the risk of SSI following colorectal procedures.\textsuperscript{178-180} The rate of SSI was higher with the sponge, however, in a recent large, multicenter randomized clinical trial.\textsuperscript{181}
      ii. Cardiothoracic surgical patients. Four randomized controlled trials have evaluated the use of gentamicin-collagen sponges in cardiothoracic surgery. Three of these trials demonstrated a decrease in SSIs,\textsuperscript{182-184} and one showed no difference.\textsuperscript{185} A recent meta-analysis combining these trials concluded that the risk of deep sternal wound infection was significantly lower in patients who received a gentamicin-collagen sponge than in patients who did not (RR, 0.62 [95% CI, 0.39–0.97]) despite significant heterogeneity among the trials.\textsuperscript{186}
   b. Gentamicin-collagen sponges are not currently approved by the FDA for use in the United States.

4. Use of bundles to ensure compliance with best practices.
   a. Bundles have been promoted as methods to improve adherence to best practices.
      b. Although generally favorable, the use of bundles for the prevention of SSI has led to mixed results, depending on which components are included.\textsuperscript{187,188}
      c. Thus, there is no consensus on the components of an effective bundle to prevent SSIs.

SECTION 5: PERFORMANCE MEASURES

I. Internal reporting

These performance measures are intended to support internal hospital quality improvement efforts and do not necessarily address external reporting needs. The process and outcome measures suggested here are derived from published guidelines, other relevant literature, and the opinion of the authors. Report process and outcome measures to senior hospital leadership, nursing leadership, and clinicians who care for patients at risk for SSI.

A. Process measures

1. Compliance with antimicrobial prophylaxis guidelines.
   a. Measure the percentage of procedures in which antimicrobial prophylaxis was appropriately provided. Appropriateness includes (1) correct type of agent, (2) start of administration of the agent within 1 hour of incision (2 hours allowed for vancomycin and fluoroquinolones), and (3) discontinuation of the agent within 24 hours after surgery.
      i. Numerator: number of patients who appropriately received antimicrobial prophylaxis.
      ii. Denominator: total number of selected operations performed.
      iii. Multiply by 100 so that the measure is expressed as a percentage.

2. Compliance with hair removal guidelines.
   a. Measure the percentage of procedures for which hair removal is appropriately performed (ie, clipping, use of a depilatory or no hair removal is performed rather than use of razor).
      i. Numerator: number of patients with appropriate perioperative hair removal.
      ii. Denominator: total number of selected operations performed.
      iii. Multiply by 100 so that the measure is expressed as a percentage.

3. Compliance with perioperative glucose control guidelines.
   a. Measure the percentage of procedures for which serum glucose is 180 mg/dL or lower within 18–24 hours after anesthesia end time for all cardiac surgery patients.\textsuperscript{60,61,100}
      i. Numerator: number of patients with appropriately maintained serum glucose (180 mg/dL or lower) in the time frame of 18–24 hours after anesthesia end time following cardiac surgery.
      ii. Denominator: total number of cardiac procedures performed.
      iii. Multiply by 100 so that the measure is expressed as a percentage.

B. Outcome measures

1. SSI rate
      i. Numerator: number of patients with an SSI following selected operations.
      ii. Denominator: total number of selected operations performed.
      iii. Multiply by 100 so that the measure is expressed as the number of SSIs per 100 procedures.
II. External reporting

A. Process measures

iv. Rates of SSI can be risk adjusted using one of 2 methods: stratification using the NHSN risk index133 or calculation of the standardized infection ratio (SIR).189 NHSN now promotes the use of SIR over the NHSN risk index for improved risk adjustment potential,190 and SIR is preferentially used for the national public reporting outcome measure within NHSN.

(a) The NHSN risk index is an operation- and patient-specific prospectively applied risk score that predicts SSIs.191 This risk index includes 3 predictors of increased risk of SSI: (1) estimators of wound microbial contamination, (2) duration of operation, and (3) markers for host susceptibility.42

(b) SIR is the ratio of the observed number of SSIs ($O$) that occurred compared with the expected number for a surgeon performing a specific type of procedure ($E$; eg, SIR = $O/E$).189 The expected number of SSIs can be obtained by multiplying the number of operations done by the surgeon in each procedure risk category by the NHSN rate for the same procedure risk category and dividing by 100. Values that exceed 1.0 indicate that more SSIs occurred than expected. Importantly, SIR can only be calculated if the number of expected HAsIs is $\geq 1$. Thus, this approach may be more difficult for small surgical programs or if few procedures are performed for any one procedure type.192

(c) Risk adjustment using logistic regression and the SIR method generally provides better risk adjustment than the basic risk index.190,193

II. External reporting

There are many challenges in providing useful information to consumers and other stakeholders while preventing unintended adverse consequences of public reporting of HAsIs.194 Recommendations and requirements for public reporting of HAsIs have been provided by HICPAC,195 the Healthcare-Associated Infection Working Group of the Joint Public Policy Committee,54 the National Quality Forum,55 and CMS.196 The following is an example of an external performance measure that is currently required by some healthcare stakeholders and regulators.

A. Process measures

1. Compliance with CMS antimicrobial prophylaxis guidelines (see the section above on internal reporting in “Section 5: Performance Measures”).

   a. Measure the percentage of procedures in which antimicrobial prophylaxis was appropriately provided. Appropriateness includes correct type of agent, administration of the agent within 1 hour of incision (2 hours are allowed for vancomycin and fluoroquinolones), and discontinuation of the agent within 24 hours after surgery (48 hours for cardiothoracic procedures).197

2. Compliance with the CMS guideline for control of postoperative blood glucose in cardiac surgery patients.

   a. Measure the percentage of procedures in which postoperative blood glucose was appropriately controlled in cardiac surgery patients.

B. Federal and state requirements

1. Federal requirements

   a. The CMS published a final rule in the Federal Register on August 18, 2011, that includes SSI reporting via the CDC’s NHSN in the CMS Hospital IQR program requirements for 2012.198 More specifically, the rule announced a reporting requirement for SSI data for inpatient abdominal hysterectomy and inpatient colon procedures beginning with surgical procedures performed on January 1, 2012.199

   b. The requirements for SSI reporting to NHSN for the IQR program do not preempt or supersede state mandates for SSI reporting to NHSN (ie, hospitals in states with an SSI reporting mandate must abide by their state’s requirements, even if they are more extensive than the requirements for this CMS program). NHSN users reporting SSI data to the system must adhere to the definitions and reporting requirements for SSIs as specified in the NHSN Patient Safety Component Protocol Manual.198 For more information, see http://www.cdc.gov/nhsn/acute-care-hospital/ssi/index.html.

2. State requirements and collaboratives

   a. State requirements. Hospitals in states that have mandatory SSI reporting requirements must collect and report the data required by the state. For information on state requirements, check with your state or local health department.

   b. State collaboratives. Currently 27 states have implemented voluntary SSI collaboratives. For more information on state collaboratives for SSI, see http://www.cdc.gov/hai/stateplans/states-w-SSI-collaborative.html.

3. External quality initiatives

   a. Several external quality initiatives focused on SSI prevention are ongoing. The benefits in participation in these external quality initiatives is unknown but may include improvement in the culture of safety and patient outcomes, including decreased rates of SSI. For additional information, see the following:

      i. http://www.ahrq.gov/qual/haify11.htm#projects

TABLE 3. Fundamental Elements of Accountability for Healthcare-Associated Infection Prevention

Senior management is responsible for ensuring that the healthcare system supports an infection prevention and control (IPC) program that effectively prevents healthcare-associated infections (HAIs) and the transmission of epidemiologically important pathogens.

Senior management is accountable for ensuring that an adequate number of trained personnel are assigned to the IPC program and adequate staffing of other departments that play a key role in HAI prevention (e.g., environmental services).

Senior management is accountable for ensuring that healthcare personnel, including licensed and nonlicensed personnel, are adequately trained and competent to perform their job responsibilities.

Direct healthcare providers (such as physicians, nurses, aides, and therapists) and ancillary personnel (such as environmental service and equipment processing personnel) are responsible for ensuring that appropriate IPC practices are used at all times (including hand hygiene, standard and isolation precautions, and cleaning and disinfection of equipment and the environment).

Senior and unit leaders are responsible for holding personnel accountable for their actions.

IPC leadership is responsible for ensuring that an active program to identify HAIs is implemented, that HAI data are analyzed and regularly provided to those who can use the information to improve the quality of care (e.g., unit staff, clinicians, and hospital administrators), and that evidence-based practices are incorporated into the program.

Senior and unit leaders are accountable for ensuring that appropriate training and educational programs to prevent HAIs are developed and provided to personnel, patients, and families.

Personnel from the IPC program, the laboratory, and information technology departments are responsible for ensuring that systems are in place to support the surveillance program.

SECTION 6: EXAMPLES OF IMPLEMENTATION STRATEGIES

Accountability is an essential principle for preventing HAIs. It provides the necessary translational link between science and implementation. Without clear accountability, scientifically based implementation strategies will be used in an inconsistent and fragmented way, decreasing their effectiveness in preventing HAIs. Accountability begins with the chief executive officer and other senior leaders who provide the imperative for HAI prevention, thereby making HAI prevention an organizational priority. Senior leadership is accountable for providing adequate resources needed for effective implementation of an HAI prevention program. These resources include necessary personnel (clinical and nonclinical), education, and equipment (Table 3).

The following information identifies implementation strategies that can be used as part of a program to prevent and reduce the risk for SSI. The implementation strategies are organized under 4 concepts: engage, educate, execute, and evaluate.

I. Engage

In the engagement phase, there needs to be clear and effective communication pertaining to the reasons why the SSI implementation strategies are important for patient care. Engagement of senior leadership, physician champions, infection preventionists, and multidisciplinary teams is an example of strategies necessary for initial implementation of a program to reduce SSIs. The following implementation strategies are described in the literature as being essential for the engagement process.

A. Obtaining support for SSI reduction from senior leadership. Senior leadership support is an important factor contributing to SSI rate decreases. Senior leadership is also critical for sustaining improvements over time.

B. Obtaining highly engaged physicians as champions. Medical and surgical staff engagement is critical for SSI prevention activities and to champion SSI prevention throughout the hospital. Examples include a physician leading an SSI prevention multidisciplinary team and a physician champion who provides education on strategies to reduce SSIs to other physicians and staff.

C. Use of multidisciplinary teams. Numerous studies and literature address the effectiveness of multidisciplinary teams to plan, develop, implement, and evaluate efforts to reduce SSIs. The key components of the team include preoperative, intraoperative, and postoperative management of the patient. Teams should include nursing, pharmacy, and physician champions.

D. Adopting evidence-based practices and guidelines. Several studies in the literature focus on the need for hospitals to adopt evidence-based practices and guidelines in an effort to decrease the risk of SSIs. The literature stresses that, although evidence-based interventions can reduce the number of SSIs and improve patient outcomes, implementation of these practices nationally occurs less frequently than is desirable.

E. Focus on a culture of safety. The literature supports the need for a culture of safety to successfully implement a program focusing on reducing SSIs. A culture of safety focuses on teamwork, technical processes, and promoting accountability for preventing SSIs throughout the continuum of care.

II. Educate

Education pertaining to practices to prevent SSIs is essential for senior leadership, physicians, nurses, and patients and families. The following implementation strat-
egies describe the types of education that can impact SSI rates and who should be the focus of educational efforts.

A. **Aligned and coordinated SSI education for licensed independent practitioners and staff.** Multidisciplinary education for licensed independent practitioners (physicians and midlevel practitioners) and other practitioner staff (registered nurses) must be aligned and coordinated. The content of the education focuses on the continuum of the patient’s care and execution of evidence-based practices to prevent SSIs.202,203

B. **One-to-one education of the surgeon when an SSI issue is identified.** Provide one-to-one education when surgeons have elevated SSI rates and/or when appropriate preventive processes are not being adhered to. This education may be conducted by another surgeon, infection preventionist, quality office, or other qualified individuals. The education should be nonconfrontational with an emphasis on understanding variation in practice rather than judgment. If lack of adherence to evidence-based practices is identified, then an action plan must be developed.203

C. **Education for senior leadership that describes the value and benefits of SSI reduction.** Provide education to executive leadership regarding the value of reducing SSIs, including patient and fiscal outcomes.131

D. **Education for the surgical team on safety science.** Provide education to licensed independent practitioners and staff involved in the care of surgical patients on the science of safety, including the principles of safe system design.200

E. **Specific SSI education for patients and families.** Patient education for reducing SSIs is a major priority for any hospital focused on preventing SSIs. Education strategies such as presurgical classes, television education, and one-to-one education with the patient and family have been used successfully. Educational materials should be provided in multiple languages on the basis of the population served.131,202,203

III. **Execute**

In the execution phase, the focus is on implementation strategies to reduce barriers and improve adherence with evidence-based practices and reduce the risk of SSIs, including (a) standardization of care processes, (b) creating redundancy or independent checks, and (c) learning from defects when an SSI occurs. As noted above, no consensus exists on the components of an effective bundle to prevent SSIs. Thus, individual hospitals must identify local deficits and create their own bundle.

A. **Use a quality improvement methodology.** Use of quality improvement methodology for designing and implementing a program leads to reduced rates of SSIs. Quality improvement methodologies include Lean Six Sigma, the Comprehensive Unit-Based Safety Program, and the Plan-Do-Check-Act model. Various performance improvement (PI) tools have been used, including dashboards, scorecards, and histograms, to display data.149,200,203,207,211

B. **Differentiate between adult and pediatric populations.** Pediatric-focused evidence-based practices for reducing SSIs are lacking. Clinical interventions designed for the adult population cannot necessarily be transferred to the pediatric population. Hospital and pediatric surgeons must determine whether adult evidence-based interventions can be safely used with the pediatric population.203

C. **Use of information technologies (IT).** IT innovations can be used to simplify and standardize clinical documentation. IT and the electronic medical record can also be used for electronic surveillance, electronic prompts, automatic stops for prophylactic antibiotic orders, and education. Education can be delivered to patients, families, and healthcare workers through different media, including the Internet and television.148,202,203,212

D. **Participation in a collaborative.** Numerous studies have reported that participation in a collaborative can help reduce SSI rates in participating organizations. Collaboratives provide a mechanism for organizations to

1. Utilize valid data, such as with the American College of Surgeons National Surgical Quality Improvement Program;213
2. Identify increased morbidity and mortality through comparisons to peer hospitals on a national basis;213 and
3. Learn through the collaboration process.161,202,203,207,210,214

E. **Use of preoperative/postoperative order sets.** Standardized order sets can be developed on the basis of evidence-based practices. The order sets should be approved by the medical staff and updated when the evidence-based practices change. The development of order sets is a labor-intensive process necessitating skills and expertise of several disciplines, including surgery, anesthesia, nursing, and pharmacy. All relevant disciplines should be educated in the use of the order sets.146,202,203

F. **Acting on identified SSI issues.** When issues suspected of increasing the risk of SSI are identified, the hospital should take action to resolve the identified issues. Several hospitals conduct root-cause analyses with a multidisciplinary team to identify the cause of the issues and any lack of adherence in the evidence-based practices.146,202,204

G. **Establish a protocol for preoperative testing.** Establish a protocol for procedure-specific preoperative testing to detect medical conditions that increase the risk of SSI. The protocol should focus on nutritional counseling if indicated, smoking cessation if indicated, preadmission infections, and reconciling medications with adjustments prior to surgery if indicated.202 If high-risk patients are identified through screening, alerts should be added to electronic medical records to ensure that all
members of the perioperative team are aware of the high-risk condition(s).

IV. Evaluate
In the evaluation phase, the focus is on the use of measurement and evaluation tools to determine the effectiveness of implementation strategies in the prevention of SSIs.

A. Use of performance improvement tools. Various PI tools can be used. PI tools include dashboards, scorecards, or histograms to display data. Additional PI tools can include root-cause analysis and failure modes and effects analysis.

B. Direct observation of evidence-based practices. As part of a hospital’s SSI improvement activities, trained observers (eg, infection preventionists, educators, nurses, and physicians) should observe surgery to assure that evidence-based practices have been implemented in the operating room. Direct observation can also be conducted for hand hygiene and surgical hand antisepsis technique. This activity is used to educate and reinforce evidence-based practices with the operating room practitioners.

C. Longitudinal evaluation of SSI rates and compliance rates. Track the success of the SSI reduction program by evaluating SSI rates over time (ie, before, during, and after the program). If specific practices or processes are identified for improvement, evaluate the compliance with evidence-based practices related to these practices and processes. Feed these data evaluations back to frontline staff.

ACKNOWLEDGMENTS

Disclaimer. S.I.B.-T.—The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Potential conflicts of interest. E.P.D. reports serving as an advisor/consultant for Merck, Baxter, Ortho-McNeil, Targanta, Rib-X, Affinium, 3M, Schering-Plough, Astellas, CareFusion, Durata, Pfizer, and Applied Medical and receiving grant support from Tetraphase. L.G. reports receiving grant support from T etaphase. L.G. reports receiving honoraria from Schering-Plough, Astellas, CareFusion, Durata, Pfizer, and Applied Medical.


Address correspondence to Deverick J. Anderson, MD, MPH, Division of Infectious Diseases, Box 102359, Duke University Medical Center, Durham, NC 27710 (deverick.anderson@duke.edu).

REFERENCES


42. Consensus paper on the surveillance of surgical wound infections. The Society for Hospital Epidemiology of America; the Association for Practitioners in Infection Control; the Centers for Disease Control; the Surgical Infection Society. *Infect Control Hosp Epidemiol* 1992;13(10):599–605.


52. Prospero E, Cavicchi A, Bacelli S, Barbadoro P, Tantucci L,


78. van Kasteren ME, Mannien J, Ott A, Kullberg BJ, de Boer AS, Gysens IC. Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor. *Clin Infect Dis* 2007;44(7):921–927.


85. Englesbe MJ, Brooks L, Kubus J, et al. A statewide assessment...


197. Medicare program; hospital outpatient prospective payment system and CY 2007 payment rates; CY 2007 update to the ambulatory surgical center covered procedures list; Medicare administrative contractors; and reporting hospital quality data. Mortality.


